Tolerance of Regular Meal Intake With Mycoprotein (TOMMY)

Status Completed

Clinical Trial Summary

This study aims to assess the impact of daily intake of 11 grams of Fermotein™ on gastrointestinal complaints and several other health related biomarkers. Furthermore, consumer acceptance is investigated. The study has a randomized parallel design. Two different treatments will be evaluated e.g. a 18-day intervention with fermotein based meals and a 18-day intervention with control meals. At the start and at the end of the intervention, a blood sample will be collected. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.

Clinical Trial Description

Fermotein™ is a mycoprotein, derived from fungi, especially produced for human consumption. It is high in protein, high in fiber, low in saturated fat and contains no cholesterol. Its functional properties and nutrient content makes them ideal to use as an ingredient for meat alternatives and other vegetarian/vegan food products. This study aims to assess the impact of frequent intake of 11 grams of Fermotein™ powder (dry) on gastrointestinal complaints and several other health related biomarkers. The primary objective is to investigate gastro-intestinal complaints during 18 days of Fermotein™ consumption. The secondary objective is to assess blood based parameters related to general health and consumer acceptance. The study has a randomized parallel design. Two different treatments will be evaluated e.g. a 18-day intervention with Fermotein™ based meals and a 18-day intervention with control meals. At the start and at the end of the intervention a blood sample will be collected. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention. ;

Study Design

Related Conditions & MeSH terms

Gastrointestinal Complication

Clinical Trial Details

NCT number	NCT04590768
Study type	Interventional
Source	Wageningen University and Research
Contact
Status	Completed
Phase	N/A
Start date	October 12, 2020
Completion date	November 2, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00936130` - Bariatric Surgery and Weight Loss on Energy Metabolism and Insulin Sensitivity	N/A
Recruiting	`NCT04880473` - Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment	N/A
Completed	`NCT03678987` - Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis
Completed	`NCT03677583` - Duckweed Intake Study	N/A
Recruiting	`NCT04192435` - Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery	Phase 4
Completed	`NCT06165523` - Kefir Versus Milk on Time-Trial Performance in Masters Athletes	N/A
Recruiting	`NCT06072976` - The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies	N/A
Recruiting	`NCT03848962` - Collection and Distribution of Biospecimens for Novel Research Uses
Recruiting	`NCT06250166` - Feasibility, Acceptability, and Effectiveness of an Individualized Plant-based (iPLANT) Diet Plan in Colorectal Cancer: Mixed Method Embedded Design	N/A
Enrolling by invitation	`NCT05080907` - Collection and Distribution of Biospecimens for Novel Research
Completed	`NCT02040285` - Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC)	Phase 4
Completed	`NCT00814086` - Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	Phase 1
Terminated	`NCT03100409` - Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients	N/A
Recruiting	`NCT04903925` - Probiotics for Improving Post-surgical Healing	N/A